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Bordetella parapertussis is a respiratory-disease pathogen producing symptomatology
similar to that of pertussis but of underestimated incidence and with no specific
vaccine existing. We recently designed a vaccine candidate from B. parapertussis
outer-membrane vesicles (OMVs) that proved to be safe and protective in a
murine-infection model. Based on protection recently reported for the B. parapertussis
O antigen in aqueous solution, we assessed here whether the B. parapertussis
O-antigen-containing lipopolysaccharide (BppLPS-O+) embedded in the membranes,
as present in B. parapertussis-derived OMVs (OMVs(Bpp-LPS-O+)), was the
component responsible for that previously observed protection by OMVs. By
performing a comparative study with OMVs from a human strain with undetectable
O antigen (OMVs(Bpp-LPS-O−)), we demonstrated that the OMVs(Bpp-LPS-O+),
but not the OMVs(Bpp-LPS-O−), protected mice against sublethal B. parapertussis
infections. Indeed, the B. parapertussis loads were significantly reduced in the
lungs of OMVs(Bpp-LPS-O+) -vaccinated animals, with the CFUs recovered being
decreased by 4 log units below those detected in the non-immunized animals or
in the animals treated with the OMVs(Bpp-LPS-O−), (p < 0.001). We detected
that the OMVs(Bpp-LPS-O+) induced IgG antibodies against B. parapertussis
whole-cell lysates, which immunocomponents recognized, among others, the O
antigen and accordingly conferred protection against B. parapertussis infection,
as observed in in-vivo–passive-transfer experiments. Of interest was that the
OMVs(Bpp-LPS-O+) -generated sera had opsonophagocytic and bactericidal
capabilities that were not detected with the OMVs(Bpp-LPS-O−)-induced sera,
suggesting that those activities were involved in the clearance of B. parapertussis.
Though stimulation of cultured spleen cells from immunized mice with formulations
containing the O antigen resulted in gamma interferon (IFN-γ) and interleukin-17
production, spleen cells from OMVs(Bpp-LPS-O+) -immunized mice did not
significantly contribute to the observed protection against B. parapertussis infection.
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The protective capability of the B. parapertussis O antigen was also detected in
formulations containing both the OMVs derived from B. pertussis and purified BppLPS-
O+. This combined formulation protected mice against B. pertussis along with B.
parapertussis.
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INTRODUCTION
Bordetella parapertussis is a species quite close to Bordetella
pertussis that can infect humans causing similar symptoms to
those of the respiratory disease referred to as pertussis. The
detection of this pathogen in pertussis patients is relatively
frequent in different countries of Europe (1, 2) and also in
the USA (3–5). In the latter country, the highest number
of B. parapertussis infections was recorded in Wisconsin (at
443 cases) between October 2011 and December 2012 (5). As
had occurred previously, during such outbreaks 11.2% of the
diagnostic specimens positive for Bordetella were also positive
for B. parapertussis, probably indicating the endemnism of
B. parapertussis. In fact, in the USA B. parapertussis was
estimated to have caused 16% of the cases diagnosed as pertussis
(6). In several countries of Latin America, infections caused
by B. parapertussis have been detected, but unfortunately no
official reports about the incidence rates are available. We
wish to note here that in general the global incidence of B.
parapertussis is probably underestimated, not only in Latin-
American countries but also in most others because the official
notification of the infections caused by this pathogen are not
mandatory. Furthermore, many laboratories do not have the
technologic wherewithal to discriminate between B. pertussis and
B. parapertussis infections. In addition, B. parapertussis must
clearly be recognized as the cause of a pertussis-like disease for
which no specific effective preventive strategies have as yet been
developed.Moreover, the currently used vaccines for pertussis are
not adequate for reducing B. parapertussis infections (7). Several
of the protective immunogens included in the pertussis vaccines,
though homologous to B. parapertussis proteins, are antigenically
distinct (7, 8). This may be one of the reasons that could explain
the observed incomplete cross-protection of pertussis vaccines
against B. parapertussis. Furthermore, these two species show
differences in the expression of components that are essential for
the protection induced by pertussis vaccines. As an example, the
pertussis toxin is only expressed by B. pertussis and since this
toxin is not present in B. parapertussis, the protective immune
response triggered by the toxin has no target in B. parapertussis.
Only two studies have indicated that pertussis acellular
vaccines could have any effect whatsoever on the control
of B. parapertussis; and as described by the authors, those
studies had several limitations—mainly as a consequence of the
underreporting of B. parapertussis, which underestimation must
necesarily affects the assessment of vaccine effectiveness (2, 9).
Even worse, Long et al., using a rodent model of bordetellosis,
demonstrated that pertussis acellular vaccination enhances the
performance of B. parapertussis (10).
The ongoing research activity on B. parapertussis points to the
demand for a specific vaccine against this pathogen. The proteins
of B. parapertussis—such as the filamentous hemagglutinin
and the iron-transport protein AfuA, among others—had been
proven to confer protection against B. parapertussis infection
in a mouse model (11, 12). In previous work, we started to
investigate the potential of outer-membrane vesicles (OMVs)
derived from B. parapertussis as an alternative approach to
a vaccine candidate against B. parapertussis (13). Using the
mouse model of intranasal infection, we observed that the
formulations based on these OMVs efficiently protected mice
against B. parapertussis infection, whereas current commercial
acellular pertussis vaccines exhibited little protection against
that particular pathogen (13). OMVs are naturally released by
various Gram-negative bacteria and contain predominantly
outer-membrane components, including the lipopolysaccharide
(LPS), along with periplasmic compounds (14). That the
isolated LPS of B. parapertussis—and in particular the LPS
containing the O antigen (BppLPS-O+)—has been found to
protect against B. parapertussis infection is noteworthy (15).
That protection was revealed by the assays carried out in a
mouse model in which immunizations were performed with
commercial acellular vaccines supplemented with an aqueous
solution containing 10 µg of purified BppLPS-O+ (15). That
protective capability was, in fact, associated specifically with
the presence of the O antigen (15). At this point, we must
stress that though all B. parapertussis has the unusual lipid A
structure characteristic to Bordetella [absence of symmetry at
the C-3 and C-3’ positions, phospate groups modified with
glucosamine and hipo-acylation, (16, 17)], not all lineages of
B. parapertussis contain an LPS whose structure includes the
O antigen. The lineage that infects only humans contains an
LPS with the O antigen, whereas the LPS of the strains that
have been recovered from sheep lack that antigen (18). We were
also interested to note that the isolates containing LPS without
the O antigen are highly sensitive to murine complement-
mediated killing in vitro, and because of that vulnerability
those B. parapertussis isolates failed to colonize naïve
mice (18).
Within this context, in the present work, we assessed whether
the B. parapertussis LPS with the O antigen embedded in the
membranes—as occurs in the example of the OMVs derived
from B. parapertussis OMVs(Bpp-LPS-O+)—would prove to be
the crucial component for the previously reported protection of
the OMVs (13). To assess the role of LPS-O+, the immunity
and protection conferred by B. parapertussis-OMV vaccination
were compared to the properties generated by the OMVs
derived from an ATCC strain of B. parapertussis in which
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the O antigen was not detected (OMVs(Bpp-LPS-O−)). Mice
immunized with OMVs derived from a clinical isolate of
B. parapertussis whose LPS contained the O antigen were
protected against B. parapertussis, but not those treated with
OMVs derived from B. parapertussis lacking that antigen. By
performing in-vitro and in-vivo experiments, we detected that
the humoral response containing O-antigen-specific antibodies
contributed to the protection induced by the OMVs(Bpp-LPS-
O+) -vaccines. In contrast, sera collected from OMVs(Bpp-
LPS-O−) immunized mice produced no such reduction of
B. parapertussis colonization upon passive transfer. Purified
BppLPS-O+, but not the BppLPS-O−, induced protection in
mice against B. parapertussis challenge. Moreover, the inclusion
of BppLPS-O+, but not BppLPS-O−, rendered the vaccine
based on OMVs derived from B. pertussis (19–24) efficacious
against both B. parapertussis and B. pertussis challenge. All
together, these data indicated that LPS-O+ is a crucial
protective antigenic component of the OMVs derived from
B. parapertussis.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Bordetella parapertussis AR729, an Argentine clinical
isolate previously used to obtain the OMVs, along with
the ATCC strain B. parapertussis 15237—the isolate from
Eldering and Kendrick lacking the LPS O antigen—were
used throughout this study (25). In contrast to other
human B. parapertussis isolates, the ATCC strain has
undetectable O antigen (18). These strains were grown
either in Bordet-Gengou agar (BGA, Difco) supplemented
with 1% (v/v) glycerol, 10 g/L Bacto peptone (Difco), and
10% (v/v) defibrinated sheep blood and incubated at 36◦C, or
alternatively in Stainer-Scholte liquid medium (26), as indicated
previously (13).
Isolation of OMVs
To obtain OMVs from the bacterial cells, we used the method
previously described by us (19, 20, 27). The procedure stated
in brief: Culture samples from the decelerating growth phase of
the bacteria were centrifuged at 10,000 x g for 20min at 4◦C
and the pellet obtained resuspended in 20mM Tris-HCl, 2mM
EDTA, pH 8.5 (TE Buffer). Of the resulting pellet, ∼1 g (wet
weight) was resuspended in 5mL of the TE Buffer. OMV release
was promoted by sonication in ice-water; the cells were then
removed by centrifugation at 10,000 x g and the OMV-containing
supernatant concentrated by ultracentrifugation at 40,000 x g for
3 h. The OMVs thus obtained were stored at 4◦C. Thereafter
the OMVs were examined by electron microscopy after negative
staining (20).
Protein Assay
The protein content was estimated by the Bradford method with
BSA as a standard (28).
LPS Sodium
Dodecylsulfate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and
Immunoblotting
The LPS from the OMVs of B. parapertussis was solubilized in
Laemmli sample buffer (29) and heated at 100◦C for 10min.
Twenty-five mg of proteinase K in 10 µL of Laemmli sample
buffer were added per 50 µL of OMV suspension. The mixtures
were incubated in a water bath at 60◦C for 1 h with occasional
vortexing. The proteinase-K–treated samples were applied to
the gels and the electrophoresis performed at room temperature
and constant voltage. The LPS visualized by the BioRad
silver-staining technique was transferred to polyvinylidene-
difluoride membranes (Immobilon P; Millipore) and probed
with OMV-immune sera (1:2,000) followed by incubation with
anti(mouse IgG) conjugated with alkaline phosphatase at a
1:1,000 dilution. Nitroblue tetrazolium and 5-bromo-4-chloro-
3-indolyl-phosphate were used as the phosphatase substrates
according to the manufacturer’s protocol (Biodynamics SRL
Buenos Aires Argentina).
Isolation of B. parapertussis LPS
The LPS from B. parapertussis was isolated by the hot phenol-
water method, along with previously described modifications
(30). The samples of LPS were dialyzed and lyophilized. Dry
weights were used to determine the amounts of LPS obtained.
The quality of each sample was checked by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE).
Formulation of Vaccines
To use the OMVs or purified LPS as acellular vaccines, vesicle
(3 µg) and LPS (1 µg) preparations were detoxified by mixing
with aqueous formaldehyde (0.37% [v/v]) and incubating at 37◦C
overnight, with aluminum hydroxide (0.2 mg/mL) thereafter
being added as an adjuvant.
Active Immunization and Intranasal
Challenge
Four-week-old female BALB/c mice (n = 12 per experimental
group) obtained from Biol SAIC, Argentina were used for all
assays. As described previously (19), the immunization protocols
comprised a two-dose schedule (i.p.) with the formulations
described above over a period of 2 weeks. Two weeks after
the second immunization, the mice were subjected to a nasal
challenge with a sublethal dose (106-107 CFUs in 40 µL) of B.
parapertussis strain AR729. Then, at 7 days after the challenge,
the lungs of the mice were excised and collected for bacterial
counts. The number of CFUs was determined as previously
described (19). These experiments were carried out in accordance
with the recommendations of the Guide for the Care and Use
of laboratory animals, National Research Council of National
Academies, Washington DC 2010 and/or Directive 2010/63/EU
on the protection of animals. The protocol was approved by
the Ethical Committee for Animal Experiments of the Faculty
of Science at La Plata National University (approval number
003-06-15).
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Enzyme-Linked Immunosorbent Assay
(ELISA)
Plates were coated with sonicated B. parapertussis whole-cell
lysates in 0.5M carbonate buffer, pH 9.5 in an overnight
incubation at 4◦C and then blocked with 3% (v/v) skimmed
milk in blocking buffer (2 h at 37◦C) before incubation with
serially diluted mouse-serum samples (1 h at 37◦C). The bound
IgG was detected after a 2-h incubation with horseradish-
peroxidase–conjugated goat anti(mouse IgG) at a titer of
1:20,000 (Thermo Fisher Scientific, Buenos Aires Argentina).
For measuring IgG isotypes, the detection of bound antibody
was determined with horseradish-peroxidase–labeled subclass-
specific anti(mouse IgG1 or IgG2a) at 1:8,000 or 1:1,000,
respectively (Sigma Aldrich, USA). The substrate used was 1.0
mg/mL o-phenylendiamine (Bio Basic Canada Inc.) in 0.1M
citrate-phosphate buffer, pH 5.0 containing 0.1% (v/v) hydrogen
peroxide. The optical densities (ODs) were measured with a
Titertek Multiskan Model 340 microplate reader (ICN, USA)
at 492 nm and the OD plotted as a function of the log of
the reciprocal serum dilution. The inflection point of the
curve was determined by the GraphPadPrims R© software. Titers
were defined as the reciprocal serum dilution giving an OD
corresponding to the inflection point of the curve.
Cell-Line Growth
Macrophage-like RAW 264.7 cells (ATCC TIB-71) were grown
in Roswell Park Memorial Institute (RPMI) 1640 medium
containing 10% (v/v) heat-inactivated fetal-bovine serum (FBS)
and an antibiotic solution of 100 international units (I U)/mL
penicillin and 100µg/mL streptomycin at 37◦C in 5% (v/v)
CO2/air.
Opsonophagocytosis Assay
A B. parapertussis strain expressing the green-fluorescent protein
(GFP)—the B. parapertussis AR729 carrying plasmid pCW504,
kindly provided byDr. A.Weiss—was opsonized by incubation at
37◦C with different serum samples added at 20% (v/v) for 30min
in a final volume of 40 µL. Serum-opsonized GFP-expressing
bacteria were incubated with RAW 264.7 cells at a multiplicity
of infection of 70 for 30min at 37◦C to enable binding and
internalization. After extensive washing to remove non-attached
bacteria, the samples were analyzed with a FACS Calibur flow
cytometer (Becton Dickinson, San Jose, CA) and the results
of the estimated degree of phagocytosis expressed as the mean
fluorescence intensity. Statistical significance was assessed by the
one-way analysis of variance (ANOVA) followed by Bonferroni’s
multiple-comparison test (GraphPadPrims R©). Differences were
considered to be significant when p < 0.001.
Bactericidal Assay
The bactericidal activity of the sera collected from mice 2
weeks after immunization with the OMV(Bpp-LPS-O+) and
OMV(Bpp-LPS-O−) vaccines (i.e., the immune sera) and from
non-immunized mice (i.e., the naïve sera) were tested in vitro.
Naïve sera from mice were used as a source of complement.
Both heat-inactivated immune and naïve sera and the vehicle
phosphate-buffered saline (PBS) alone were used as controls.
Virulent B. parapertussis were grown on Bordet Gengou agar
medium and diluted to 1 × 105 CFUs/mL in PBS containing
MgCl2 0.05M and CaCl2 0.15mM. Forty-five microliters of heat
inactivated serum or PBS were mixed with 5 µL of a suspension
containing 500 CFUs of the bacteria. After 1 h of incubation at
37◦C, 5 µL of naïve serum was added to each of the samples
tested. After 1 h of incubation at 37◦C, serial dilutions of the
samples were spread on Bordet Gengou agar plates and incubated
for 48–72 h to determine the CFUs. At least three biological
replicates were performed.
Analysis of the Cellular Response Elicited
by Vaccination
The cellular response was analyzed as previously described
(21, 31). Briefly, spleen cells from mice immunized with the
OMV-based vaccines were harvested 8 weeks after the last
immunization and seeded in 48-well culture plates at 106
per well in a volume of 500 µL of RPMI 1640 cell-culture
medium supplemented with 10% (v/v) fetal-bovine serum
(Invitrogen, Buenos Aires Argentina) containing 100 IU/mL
penicillin and 100µg/mL streptomycin. All the spleen cells were
either stimulated with OMVs derived from B. parapertussis
(5µg/mL) or exposed to medium alone. Supernatants were
removed after 72 h of incubation at 37◦C in an atmosphere
of 5% (v/v) CO2/air and the production of interferon-γ
(IFN-γ), and IL-17 determined by ELISA (BD Biosciences,
CA USA), according to the conditions specified by the
manufacturer.
Adoptive Transfer
Pooled sera (100 µL) or spleen cells (5 × 107) from non-
immunized mice or from mice immunized with the OMV-
or LPS-based vaccine 2 weeks previously were transferred
intraperitoneally to female BALB/c mice (n = 12). Twenty-four
h thereafter, the mice were infected with a sublethal dose (106-
107 CFUs 40 inµL) of B. parapertussisAR729 and the subsequent
protection assessed by determining the CFU counts in the mouse
lungs 7 days after the challenge.
Statistical Analysis
The data were evaluated statistically by the Student t-test or
the ANOVA followed by the Bonferroni post-hoc test (via
the GraphPad Prism R© software) as indicated in the legends
to the figures. Differences were considered significant at a p
<0.05.
RESULTS
Isolation and Characterization of the OMVs
Obtained From B. parapertussis AR729
and ATCC 15237 Strains
The OMV samples obtained from B. parapertussis AR729 and
B. parapertussis ATCC 15237 grown in the virulent phase
were negatively stained and examined by electron microscopy
(Figure 1A). The procedure was repeated at least four times,
and in all the samples the size range (at dimensions of 50–
150 nm) was both consistent from batch to batch and similar to
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FIGURE 1 | Characterization of OMVs by electron microscopy and electrophoresis. (A) Transmission-electron-microscopy image of the negatively stained
preparations obtained in the virulent phase from B. parapertussis strains AR729 (OMVs(Bpp-LPS-O+)) and ATCC 15237 (OMVs(Bpp-LPS-O−)). Scale bar: 200 nm.
(B) LPS analysis of OMVs(Bpp-LPS-O+) and OMVs(Bpp-LPS-O−) by 15% (w/v) SDS-PAGE. The bands were visualized by the BioRad silver-staining technique. In the
figure, the sources of the samples are indicated either above (A) or below (B) the representative illustrations. (C) Immunoblotting of purified B. parapertussis LPS
separated by 15% (w/v) SDS-PAGE probed with the specific O antigen polyclonal antiserum obtained from mice. The arrows indicate the locations of the O antigen
(O-Ag) and the Band B.
that previously described for OMV preparations derived from B.
pertussis (19) and B. parapertussis (13). To characterize the LPS
in both OMVs, one-dimensional electrophoresis was performed
(Figure 1B). By this technique, we detected that the LPS present
in the OMVs preparation derived from B. parapertussis AR729
had the characteristic electrophoretic profile of the LPS belonged
from human strains of B. parapertussis (16, 32) consisting in
a faster-migrating LPS—B band that corresponds to the Lipid
A- core structure together with a ladder arrangement of high
molecular mass bands that correspond to the O antigen (O-Ag,
a polymer of 2,3-diacetamido-2,3-dideoxy-α-galacturonic acid
(33)). The presence of the O-Ag band in the LPS from AR729
was confirmed by an immunoblot assay using a polyclonal serum
that only recognized the O antigen (Figure 1C). In contrast, the
LPS from the OMVs derived from the ATCC 15237 strain did not
contain the characteristic O-Ag band. Moreover, the polyclonal
serum against O antigen did not react with this LPS derived from
ATCC15237 strain (Figure 1C).
Protection Against Intranasal
B. parapertussis Challenge After
Vaccination With OMVs Obtained From
Different Strains
To evaluate the protective capability against B. parapertussis
challenge of the OMVs obtained either from B. parapertussis
AR729 (OMVs(Bpp-LPS-O+)) or B. parapertussis ATCC 15237
(OMVs(Bpp-LPS-O−)), we used the murine model of intranasal
infection (n = 12 mice per experimental group). The CFUs
recovered from the lungs of the immunized mice were compared
with those detected in non-immunized mice (Figure 2).
Significant differences were obtained in the lung bacterial
counts between the OMVs(Bpp-LPS-O+)-immunized and
non-immunized mice (p < 0.001; Figure 2A) and also between
the OMVs(Bpp-LPS-O+) -immunized and the OMVs(Bpp-
LPS-O−) -immunized mice. The number of colonies recovered
from the lungs of the OMVs(Bpp-LPS-O+) -immunized mice
at Day 7 after challenge was at least 4.5 logs lower than those
detected in the other two groups of animals included in the
assays (Figure 2A).
We next sought to investigate if the different protective
capabilities detected for the two OMVs studied here correlated
with the corresponding LPSs purified from those OMVs from the
two strains of B. parapertussis. To that end, we performed in-vivo
protection assays using the LPSs isolated from the OMVs derived
from each strain, BppLPS-O+ and BppLPS-O−, as vaccines. Mice
(n= 12 per each group) were accordingly immunized twice with
the purified LPSs (1 µg) and then challenged 2 weeks after the
second immunization with a sublethal dose of B. parapertussis
AR729 strain, with non-immunizedmice being used as a negative
control. For the LPS-O+ used in the immunization schedule, but
not for the LPS-O−, highly significant differences of more than
4.5 logs in the lung B. parapertussis colony-formation counts
were obtained between the LPS-O+ immunized animals and
the negative control group or the LPS-O−-immunized animals
(p < 0.001; Figure 2B). Consistent with the role of the O antigen
in conferring immune protection, when the purified LPS-O+ was
added to the formulation based on the OMVs(Bpp-LPS-O−),
protection against B. parapertussis infection was restored to the
levels detected for the OMVs(Bpp-LPS-O+) vaccine (Figure 2C).
As would be expected, no such restoration occurred when the
same trial was performed with the purified LPS-O− (Figure 2C).
Since the B. parapertussis ATCC 15237 failed to colonize
the lungsof mice, protection assays using this strain
for the challenge were not performed. The failure in
colonization of this strain containing an LPS without the
O antigen was expected based on the results reported by
Zhang et al. (15).
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FIGURE 2 | Effect of active immunization on the protection of mice against B. parapertussis infection. (A) Groups of animals were immunized with
OMVs(Bpp-LPS-O+), OMVs(Bpp-LPS-O−) or non-immunized. (B) Groups of animals were immunized with BppLPS-O+, BppLPS-O− or were non-immunized. (C)
Groups of animals were immunized with OMVs(Bpp-LPS-O−) supplemented with BppLPS-O+, OMVs(Bpp-LPS-O−) supplemented BppLPS-O− or were
non-immunized. For all panels, the challenge was performed with B. parapertussis AR729 (5 x 107 CFUs in 40 µL) as the pathogen. In each of the three panels, the
number of bacteria recovered from the mouse lungs, expressed as the log10 of the means ± SEM (error bars) of the CFUs per lungs, is plotted on the ordinate for the
samples from the lungs of the experimental groups indicated on the abscissa. Graphs show values for individual mice and the median value (bar, n = 12 mice) at 7
days after challenge. The dotted horizontal line marks the lower limit of detection. The asterisks (*) indicate significant differences at a p <0.001 (ANOVA followed by
the Bonferroni post-hoc test).
Key Role of the Humoral Immune
Response Induced by the
OMVs(Bpp-LPS-O+) That Recognized,
Among Others, the O Antigen in the
Protection Against B. parapertussis
To characterize the humoral immune response induced by
the OMV based vaccine that induced protection against B.
parapertussis [OMVs(Bpp-LPS-O+)], we first determined the
total IgG and IgG isotypes titers by ELISA assays. The ELISA
results showed that mice immunized with OMVs(Bpp-LPS-O+)
produced high titers of IgG (1,460 ± 210) with an IgG1/IgG2a
ratio >1 (the species IgG1 = 656 ± 136 and IgG2a = 315 ±
83; therefore IgG1/IgG2a = 2.08). Then and based on previously
reported role of the O-Ag antibodies in protection (15) we
wanted to ascertain whether the LPS-O+ embedded in the
OMVs(Bpp-LPS-O+) was able to induce specific antibodies
against the O-Ag and, as a consequence, the induced immune
sera have protective capability against B. parapertussis infection.
To this end, we performed immunoblotting assays using purified
B. parapertussis LPS-O+ from B. parapertussis AR729 strain as
the antigen and LPS-O− from B. parapertussis ATCC 15237 for
comparison, and probed against sera from OMVs(Bpp-LPS-O+)
and OMVs(Bpp-LPS-O−) immunized mice. Significantly, in this
assay the OMVs(Bpp-LPS-O+) immune sera recognized a diffuse
band that corresponded specifically to the LPS containing the O
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FIGURE 3 | Humoral response induced by purified BppLPS-O+ and OMVs(Bpp-LPS-O+). (A) Immunoblotting of purified B. parapertussis LPS separated by 15%
(w/v) SDS-PAGE probed with the polyclonal antiserum obtained from mice immunized with OMVs(Bpp-LPS-O+) and OMVs(Bpp-LPS-O−). The arrows indicate the
locations of the O antigen (O-Ag) and the Band B that were recognized by the antiserum used in the subsequent immunoblotting indicated below the gels. These sera
are designated according to the immunogen— OMVs(Bpp-LPS-O+) and OMVs(Bpp-LPS-O−)—used to raise the immune response in the donor mice. (B)
Immunoblotting of OMVs(Bpp-LPS-O+) and OMVs(Bpp-LPS-O−) samples separated by 12.5% (w/v) SDS-PAGE and probed with the polyclonal antiserum obtained
from mice immunized with OMVs(Bpp-LPS-O+) and OMVs(Bpp-LPS-O−). The arrows indicate the locations of the O antigen (O-Ag) and the Band B that were
recognized by the antiserum used in the immunoblotting indicated below the gels. These sera are designated according to the immunogen—OMVs(Bpp-LPS-O+ )
and OMVs(Bpp-LPS-O−)—used to raise the immune response in the donor mice. (C) Effect of passive immunization with sera collected from OMVs(Bpp-LPS-O+) -
or OMVs(Bpp-LPS-O−) -immunized mice. Pooled sera from either OMVs(Bpp-LPS-O+) - or OMVs(Bpp-LPS-O−) -immunized mice were tested by transfer to naive
(Continued)
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FIGURE 3 | female mice (n = 12). Pooled sera from non-immunized mice transferred to naive female mice were used as a negative control of protection. Twenty-four
h after the transfer, the mice were infected with B. parapertussis AR729 as the challenge bacterium (5 × 107 CFUs in 40 µL). In the figure, the number of bacteria
recovered from the mouse lungs, expressed as the log10 of the means ± SEM (error bars) of the CFUs per lungs, is plotted on the ordinate for the non-immune and
the two immune sera indicated on the abscissa, with the latter being designated according to the immunogen—OMVs(Bpp-LPS-O− ) and OMVs(Bpp-LPS-O+)
—used to raise the immune response in the donor mice. The asterisk (*) indicates a significant difference vs. the naïve sera (p ≤0.05). (D) Opsonophagocytic activiy of
the immune sera. The mean fluorescence intensity in arbitrary units (AU) associated with macrophages previously incubated with GFP-expressing B. parapertussis
AR729 is plotted on the ordinate for each of the sera used for opsonization of those bacteria on the abscissa, indicated as non-immune or immune, with the latter
being designated according to the immunogen—OMVs(Bpp-LPS-O−) and OMVs(Bpp-LPS-O+)—used to raise the immune response in the donor mice. The asterisk
(*) denotes p ≤ 0.0001 vs. the intensity obtained after exposure of the bacteria to the non-immunized serm. (E) Serum-complement–mediated killing. Sera from
OMVs(Bpp-LPS-O+)—or OMVs(Bpp-LPS-O−)-immunized mice were incubated with B. parapertussis AR729 (500 CFU), and 1 h later the bacteria were plated to
determine viability. In the figure, the percent survival is plotted on the ordinate for the non-immune and the two immune sera indicated on the abscissa, with the latter
being designated according to the immunogen—OMVs(Bpp-LPS-O−) and OMVs(Bpp-LPS-O+)—used to raise the immune response in the donor mice. The asterisk
(*) indicates a significant difference vs. the naïve sera (p ≤ 0.05).
antigen (Figure 3A, left lane). This band was not detected in the
O-antigen–deficient LPS isolated from the B. parapertussisATCC
15237 strain (Figure 3A). In contrast, the sera from OMVs(Bpp-
LPS-O−)-treated mice recognized only the fast-migrating Band
B (Figure 3A, right lane). Naïve sera did not react with either
of the bands detected in the SDS-PAGE for both LPSs (not
shown). When the OMV-generated immune sera were used
in immunoblotting assays, in which the OMVs from both the
O-antigen-positive and -negative B. parapertussis strains were
used as antigens, the polypeptide profile recognized was similar
for both sera. The major difference observed between the two
sera and the two OMV preparations, was the diffuse band
corresponding to the O antigen detected in the OMVs(Bpp-
LPS-O+) sample by the OMVs(Bpp-LPS-O+) sera (Figure 3B,
leftmost lane).
With the immune sera induced by OMVs(Bpp-LPS-O+)
having been characterized in this manner, serum-transfer
experiments were performed. The sera to be tested were
adoptively injected into naïve animals (n = 12) 24 h before
an intranasal challenge with B. parapertussis (5 × 107
CFUs B. parapertussis AR729). Sera from OMVs(Bpp-LPS-O−)
immunized mice and from naïve mice were used as negative
control of protection. Through this assay, we detected that
B. parapertussis was cleared from the mouse lungs by Day
7 after the inoculation with the OMVs(Bpp-LPS-O+) sera
containing anti-O Ag antibodies (at a reduction of 4 logs),
whereas the OMVs(Bpp-LPS-O−) or naïve sera in which anti-
O Ag antibodies were not detected had no significant effect
(Figure 3C).
To elucidate the mechanisms involved in the protective
capacity of the OMVs(Bpp-LPS-O+) immune sera, we decided
to perform an oposonophagocytosis assay since this activity
was previously associated with the presence of antibodies
against the B. parapertussis O antigen (15). Consistent with
the ELISA results demonstrating that mice immunized with
OMVs(Bpp-LPS-O+) produced high titers of IgG with an
IgG1/IgG2a ratio >1, B. parapertussis was efficiently opsonized
by the antibodies from OMVs(Bpp-LPS-O+) -induced serum
(Figure 3D). We need to remark however, that the immune
sera from OMVs(Bpp-LPS-O−) -treated mice also presented
oposonophagocytic activity. These results are not surprising since
other opsonins are expected to be induced by OMVs because
of the wide variety of immunogens present. No significant
internalization was detected for bacteria opsonized with naïve
serum (Figure 3D).
To determine whether the different degree of protection
observed for the two OMV vaccines was correlated with a
differential bactericidal capability between the sera induced
by both OMVs, killing assays were performed. For these
determinations, a suspension of 500 CFUs of B. parapertussis
bacteria was incubated in 50 µL of 90% (v/v) serum in PBS to
insure that the serum components were not limiting. These assays
revealed that the B. parapertussis bacteria were sensitive to the
immune sera induced by the OMVs(Bpp-LPS-O+), with only
24.6 ± 10.2% surviving, but resistant to OMVs(Bpp-LPS-O−)
and naïve sera, with respective percent survivals of 92.8 ± 20.5
and 92.8±11.2 (Figure 3E). In control experiments using heat-
inactivated sera, we observed a 100% bacterial survival for both
the immune and the naïve sera.
All the results presented here indicated that the presence of
O-Ag embedded in the OMVs(Bpp-LPS-O+) induced humoral
immune responses that conferred a definitive protection against
B. parapertussis. The protective capability observed seems to be
mainly a consequence of the bactericidal activity of the immune
sera.
To investigate whether the immune spleen cells, and
more specifically the T-cells, were also involved in the
immunogenicity and protection conferred by the OMVs(Bpp-
LPS-O+) formulation, we performed spleen-cell–activation and
–proliferation assays and adoptive-transfer experiments. The
results of the activation assays (Figure 4) revealed that 2
months after immunization, OMVs(Bpp-LPS-O+) vaccination in
contrast to non-immunized mice induced high concentrations
of IFN- γ (844 ± 59 pg/mL; Figure 4A) and IL-17 (244
± 61 pg/mL; Figure 4A). Similar data for both cytokines
were detected in mice immunized with OMVs(Bpp-LPS-
O−) (Figure 4A). These findings strongly indicated that
vaccination with any of the two OMV vaccines used here,
induced a mixed Th1-Th17 spleen-cell immune-response
profile.
To perform adoptive-transfer assays, naïve BALB/c mice were
treated either with 5 x 107 intact spleen cells from mice that
had been immunized with OMVs(Bpp-LPS-O+) or OMVs(Bpp-
LPS-O−) vaccine 2 weeks before or with spleen cells from non-
immunized animals. Twenty-four h later, the mice (n = 12 per
group) were infected with 5 x 107 CFUs of B. parapertussisAR729
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FIGURE 4 | Immune response induced by active immunization with
OMVs(Bpp-LPS-O+) vaccine. (A) Cytokine production by spleen cells from
immunized mice. BALB/c mice were non-immunized or immunized with two
doses of OMVs(Bpp-LPS-O+) or OMVs(Bpp-LPS-O−) vaccine. Two months
after the last immunization, mice were sacrificed and their spleen cells
exposed to OMVs(Bpp-LPS-O+), OMVs(Bpp-LPS-O−) or to medium alone
(negative control). After 72 h of culture, the concentrations of IFN- γ and IL-17
(A) were determined in the culture supernatant by ELISA. In both cases, the
concentration of cytokine in pg/mL is plotted on the ordinate for exposure of
spleen cells from non-immunized mice (white bars) or mice immunized with
OMVs(Bpp-LPS-O+) (black bars) or with OMVs(Bpp-LPS-O−) (gray bars) to
either medium alone, medium + OMVs(Bpp-LPS-O+) or medium +
OMVs(Bpp-LPS-O−), as indicated on the abscissa. The results are expressed
as mean values (± standard error) (n = 12 mice per group). Significant
differences were analyzed for each cytokine between non-immunized and
immunized mice (*p ≤ 0.01, ANOVA followed by the Bonferroni post-hoc test).
(B) Effect of passive immunization with spleen cells collected from
OMVs(Bpp-LPS-O+) or OMVs(Bpp-LPS-O−) -immunized mice. Whole spleen
cells (2–5 × 107) from OMV-immunized or non-immunized mice were tested
as possible vehicles of immune protection by passive transfer to naïve mice (n
= 12 per group). Twenty-four h after transfer, the mice were infected with B.
parapertussis AR729 (5 × 107 CFU/40 µL). In the panel, the log10 means ±
SEM (error bars) of bacteria per lungs is plotted on the ordinate for mice
receiving spleen cells from non-immunized donor mice or from those
immunized with OMVs(Bpp-LPS-O+) or with OMVs(Bpp-LPS-O−), as
indicated on the abscissa. The data are the means of 12 mice per group at 7
days postchallenge. The dotted horizontal line marks the lower limit of
detection. The results were analyzed by ANOVA followed by the Bonferroni
post-hoc test.
and then sacrificed 7 days later to determine the number of CFU
counts in the lungs (Figure 4B). The transfer of spleen cells from
immunized animals with any of the two OMV vaccines used here
resulted in a non-reduction of bacterial colonization, with the
CFU counts in the animals that received immune or naïve spleen
cells being statistically indistinguishable.
These results indicate that spleen cell-mediated immunity
would appear not to play a significant role in the protection
against B. parapertussis induced by the OMVs(Bpp-LPS-O+)
vaccine.
Protection Against Intranasal B. pertussis
Challenge After Vaccination With OMV
From B. pertussis Supplemented With
Purified B. parapertussis LPS-O
In view of the protective capabilities of OMVs derived
from B. pertussis (OMVsBp) against B. pertussis infection
and of the purified B. parapertussis LPS-O+ against B.
parapertussis challenge, we wanted to evaluate whether a
combined experimental vaccine containing OMVsBp plus
purified LPS-O+ was able to confer a simultaneous protection
against both pathogen infections at a comparable level with
respect to that of the individual vaccines (OMVsBp vaccine
and LPS-O+ vaccine). To that end, we analyzed the effect
of a double-dose–immunization schedule using a preparation
containing OMVsBp plus the purified B. parapertussis LPS-
O+ on the subsequent lung colonization of mice challenged
with B. pertussis Tohama phase I strain or B. parapertussis
AR729 (≈107 CFUs in 40 µL; Figure 5A,B). The results were
compared with those obtained for mice that had been immunized
with each of the two vaccines— OMVsBp and BppLPS-O+–
exclusively (Figure 5). PBS-injected mice served as a negative
control. Significant differences in the lung bacterial counts
between the immunized animals and the negative control group
were observed (p < 0.05; Figure 5). The protection induced by
a OMVsBp plus purified LPS-O+ vaccine against B. pertussis
challenge reached the same level as that induced by the OMVsBp
immunization alone, with the number of CFUs recovered from
the lungs at Day 7 after the challenge likewise dropping by at least
3 orders of magnitude compared to that of the non-immunized
mice (Figure 5A). Similar results were observed conversely for
B. parapertussis challenge: the number of B. parapertussis CFUs
recovered from the lungs at Day 7 after challenge likewise
dropped by at least 3 orders of magnitude in mice immunized
either with OMVsBp plus purified LPS-O+ vaccine or with LPS-
O+ vaccine alone compared to the level of infection occurring in
the non-immunized mice (Figure 5B).
The results presented in this section thus demonstrated that
the vaccines based on OMVs of B. pertussis and on the LPS-O+
of B. parapertussis could be combined without altering the levels
of protection inducible by each one independently.
DISCUSSION
We recently identified a novel vaccine candidate against B.
parapertussis consisting of the bacterial outer-membrane vesicles
(13). In previous work we had presented results on the protection
conferred by this OMV-based vaccine formulation against B.
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FIGURE 5 | Effect of active intraperitoneal immunization with OMVsBp and/or BppLPS-O+ vaccine in the mouse-intranasal-challenge model. Female mice (n = 12
per treatment) were vaccinated twice with a OMVsBp + BppLPS-O+ vaccine at a 2-week interval. Immunization with OMVs derived from B. pertussis or the LPS-O+
from B. parapertussis alone were used as controls. (A) B. pertussis Tohama was used as the challenge bacterium (5 × 107 CFUs in 40 µL). (B) B. parapertussis
AR729 was used as challenge bacterium (5 × 107 CFUs in 40 µL). In both panels, the number of bacteria recovered from the mouse lungs, expressed as the
log10(CFUs) per lungs ± SEM (error bars) is plotted on the ordinates for non-immunized mice or for those immunized with a vaccine containing OMVsBp and/or the
O-antigen–containing lipopolysaccharide LPS-O+, as indicated on the abscissa. Graphs show values for individual mice and the median value (bar, n = 12 mice) at 7
days after challenge. The dotted horizontal line marks the lower limit of detection. The asterisks (*) indicate significant differences at a p < 0.05 (ANOVA followed by
the Bonferroni post-hoc test).
parapertussis but also against infections caused by B. pertussis.
In view of the results of Zhang and colleagues on the protective
capability of B. parapertussis LPS containing the O antigen in its
structure (15), we decided to analyze whether OMVs containing
this LPS embedded within possessed the same ability to confer
protection and, if so, to analyze to what extent that component
was responsible for the protective capability (15, 34). In order to
achieve these objectives, we carried out comparative studies with
a strain of B. parapertussis in which we detected the presence
of an LPS lacking the O antigen. This detection was potentially
both relevant and informative because that strain ATCC 15237
of B. parapertussis was isolated by Kendrick and Eldering in
1938 from a human patient with symptoms similar to pertussis
(25). To the best of our knowledge, that finding constituted the
first description of a human isolate in which the O antigen was
not detected. This finding allowed us to perform comparative
protection assays, using the intranasal-challenge model in mice,
with vaccines based on vesicles derived from the Argentine strain
containing the LPS with the O antigen and the ATCC strain
lacking that O antigen. These assays enabled us to ascertain the
role of the vesicle LPS with O antigen in conferring protection.
Thus, while the OMVsBpp containing the LPS with the O antigen
adequately protected mice against B. parapertussis infection, the
presence of LPS without that key antigen in theOMVswas unable
to attain the levels of protection afforded by the OMVs(Bpp-LPS-
O+) -based immunogen. The differential protective capability
associated with the presence of the O antigen was confirmed
with preparations of purified LPS-O+ or LPS-O− as vaccines.
Furthermore, the LPS-O+ provided a protection against B.
parapertussis infections even when combined with OMVsBpp
containing LPS devoid of the O antigen or with OMVs derived
from B. pertussis which was previously described as an atractive
vaccine candidate againt B. pertussis infection containing an
important number of protective immunogens (20, 22, 23). Of
particular significance in that last formulation combining the
OMVs of B. pertussis with the LPS-O+ from B. parapertussis
was the ability to protect mice against infections caused by
either Bordetella species—a feature of considerable relevance to
pertussis epidemiology with respect to both B. pertussis and B.
parapertussis.
The results presented here demonstrate that LPS-O+ is a
protective immunogen even within the internal environment of
OMVsBpp.
Antibodies raised against B. parapertussis LPS-O+ or
OMVs(Bpp-LPS-O+) efficiently cleared B. parapertussis from
mouse lungs (Figure 3). In contrast, the immune sera from B.
parapertussis LPS lacking the O antigen and from OMVs(Bpp-
LPS-O−) are much less effective in killing the bacteria in vitro or
in mediating bacterial clearance in vivo than sera induced by the
formulations containing B. parapertussis vesicles with LPS-O+
(Figure 3).
Regarding the bactericidal activity of naïve sera and the
sensitivity of B. parapertussis to the non-immune complement,
the ovine B. parapertussis lacking the O antigen was previously
reported to be highly sensitive to murine complement-mediated
killing in vitro (18). Conversely, the O antigen was found
to enable B. parapertussis to efficiently colonize the lower
respiratory tract by protecting against complement-mediated
control and clearance (35). The results presented here are in
agreement with previous reports (18, 35) demonstrating that B.
Frontiers in Immunology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 2501
Bottero et al. Key Component in Bordetella parapertussis-OMV Protection
parapertussis strains harboring the O antigen were resistant not
only to naïve sera but also to the sera induced by the OMVs(Bpp-
LPS-O−) (Figure 3F). In contrast, Wolfe et al demonstrated
that the complement of immune animals is required for the
killing function of serum antibodies against B. parapertussis (36).
The present study of OMVs(Bpp-LPS-O+) -antibody–mediated
clearance of B. parapertussis furthermore suggests that antibody-
opsonized bacteria, in fact, activate the complement cascade,
a mechanism of clearance that is in agreement with the one
proposed by Wolfe et al. (36).
In these experiments, we also detected that the OMVs derived
from B. parapertussis, as likewise occurs with those derived from
B. pertussis (21, 31), were able to induce a Th1-Th17 profile.
Nevertheless, in contrast to the OMVs derived from B. pertussis
(31), we observed that immune spleen cells do not contribute
to the protection exhibited by the OMVBpp-based vaccine:
rather, that vaccine seems to protect against B. parapertussis
infection mainly through the induction of a humoral immune
response, as was evidenced by the adoptive-transfer experiments.
In conclusion, the body of this work has demonstrated that the
O antigen constitutes a crucial immunogen—indeed, a sine qua
non—in the formulation of the OMVBpp-based vaccine.
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